NAA30: A Potential Drug Target and Biomarker for Neurodegenerative Disorders

Target Name: NAA30

NCBI ID: G122830

NAA30

NAA30: A Potential Drug Target and Biomarker for Neurodegenerative Disorders

Neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's diseases are some of the most common forms of debilitating brain disorders that affect millions of people worldwide. These conditions are characterized by the progressive loss of brain cells and the supportive infrastructure that supports them, leading to a range of symptoms such as cognitive decline, motor dysfunction, and behavioral changes. The underlying causes of these diseases are still not fully understood, but research has identified several potential drug targets and biomarkers that may help to illuminate their pathophysiology. In this article, we will focus on one such potential drug target and biomarker, NAA30.

The neurotransmitter acetylcholine is a critical molecule in the communication network of the brain, responsible for transmitting signals between neurons and modulating the properties of neuronal membranes. The levels of acetylcholine in the brain are regulated by N-acetyltransferase (NAT), an enzyme that adds an acetyl group to specific amino acids in the neurotransmitter. NAA30 is a specific member of the NAT family that is expressed in the brain and has been implicated in the regulation of acetylcholine levels.

The NAA30 gene was identified as a potential drug target for neurodegenerative diseases due to its involvement in the regulation of critical neurotransmitter levels. Studies have shown that individuals with NAA30 genetic variants are at increased risk for developing neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Additionally, overexpression of NAA30 has been shown to increase the risk of neurodegenerative diseases in animal models of these conditions.

Furthermore, NAA30 has also been shown to be a potential biomarker for neurodegenerative diseases. The levels of NAA30 have been shown to decline in the brains of individuals with neurodegenerative conditions, and levels of NAA30 have been used as a biomarker to track the progression of these conditions. This suggests that NAA30 may be a useful diagnostic tool for neurodegenerative diseases and could potentially serve as a therapeutic target.

In addition to its potential clinical applications, NAA30 has also been shown to play a role in the pathophysiology of neurodegenerative diseases. Studies have shown that NAA30 is involved in the regulation of the levels of a neurotransmitter called glutamate, which is known to play a role in the development of neurodegenerative diseases. Additionally, NAA30 has been shown to interact with other proteins involved in neurodegenerative diseases, including the protein tau.

The potential drug target for NAA30 is the prevention and treatment of neurodegenerative diseases. Drugs that target NAA30 have the potential to slow the progression of these conditions and potentially reverse some of the cognitive and behavioral changes associated with these diseases. Additionally, by identifying individuals with NAA30 genetic variants, researchers may be able to develop targeted therapies that can treat these conditions specifically and avoid the potential side effects of traditional therapies.

In conclusion, NAA30 is a potential drug target and biomarker for neurodegenerative diseases. The regulation of acetylcholine levels by NAA30 is a critical mechanism that may play a role in the development and progression of these conditions. Identification of individuals with NAA30 genetic variants may provide insight into the pathophysiology of neurodegenerative diseases and the potential for targeted therapies. Further research is needed to fully understand the role of NAA30 in neurodegenerative diseases and to develop effective treatments.

Protein Name: N-alpha-acetyltransferase 30, NatC Catalytic Subunit

Functions: Catalytic subunit of the N-terminal acetyltransferase C (NatC) complex. Catalyzes acetylation of the N-terminal methionine residues of peptides beginning with Met-Leu-Ala and Met-Leu-Gly. Necessary for the lysosomal localization and function of ARL8B sugeesting that ARL8B is a NatC substrate

The "NAA30 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NAA30 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets